Compartilhar
Informação da revista

Estatísticas

Siga este link para acessar o texto completo do artigo

PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RR Barretoa, K Patelb, C Coombsc, N Shahd, T Eyree, W Wierdaf, P Ghiag, M Davidsh, W Jurczaki, A Matoj
a Eli Lilly and Company (Lilly), São Paulo, SP, Brazil
b Swedish Cancer Institute, Seattle, United States
c University of North Carolina at Chapel Hill, Chapel Hill, United States
d Medical College of Wisconsin, Milwaukee, United States
e Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
f MD Anderson Cancer Center, Houston, United States
g Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
h Dana-Farber Cancer Institute and Harvard Medical School, Boston, United States
i Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
j Memorial Sloan Kettering Cancer Center, New York, United States
Ver más
Lido
1334
Vezes
que se leu este artigo
543
Total PDF
791
Total HTML
Compartilhar estatísticas
Informação do artigo
ISSN: 25311379
Idioma original: Inglês
Dados atualizados diariamente
Ano/Mês Html Pdf Total
2025 7 11 3 14
2025 6 47 17 64
2025 5 64 14 78
2025 4 38 11 49
2025 3 46 13 59
2025 2 41 21 62
2025 1 33 23 56
2024 12 29 11 40
2024 11 27 18 45
2024 10 40 31 71
2024 9 41 19 60
2024 8 40 20 60
2024 7 46 24 70
2024 6 35 25 60
2024 5 40 21 61
2024 4 33 14 47
2024 3 24 24 48
2024 2 21 31 52
2024 1 12 11 23
2023 12 12 18 30
2023 11 15 21 36
2023 10 14 28 42
2023 9 11 20 31
2023 8 9 15 24
2023 7 9 6 15
2023 6 9 13 22
2023 5 9 13 22
2023 4 4 5 9
2023 3 4 6 10
2023 2 6 11 17
2023 1 5 4 9
2022 12 7 15 22
2022 11 6 11 17
2022 10 3 6 9
Mostrar tudo

Siga este link para acessar o texto completo do artigo

Idiomas
Hematology, Transfusion and Cell Therapy